Search
Ginkgo Bioworks Holdings Inc
DNAAdd to Watchlist
10.400USD
+0.110+1.07%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
641.27MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Ginkgo Bioworks Holdings Inc is 4.67, ranking 339 out of 387 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 14.00 and a low of 9.00.
Analyst Rating
Based on
3
analysts
Sell
Current Rating
10.000
Target Price
-2.72%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Ginkgo Bioworks Holdings Inc
DNA
3
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Ginkgo Bioworks Holdings Inc's expected revenue for the next quarter?
Ginkgo Bioworks Holdings Inc's expected revenue is 24.85M.
What is Ginkgo Bioworks Holdings Inc's price target?
Analysts forecast that Ginkgo Bioworks Holdings Inc's price target is USD 9.00, with the highest forecast at USD 14.00 and the lowest forecast at USD 9.00.
How have Ginkgo Bioworks Holdings IncDNA's recent earnings per share performed?
The market expectation was USD -1.39, while Ginkgo Bioworks Holdings IncDNA's earnings per share (EPS) for the previous quarter was USD -1.41. EPS for the next quarter is expected at USD -0.91.
What is the analyst rating for Ginkgo Bioworks Holdings Inc?
Based on the ratings of Ginkgo Bioworks Holdings Inc's stock from 3 analysts, most analysts support a Sell trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Sell. Please note that this is not trading advice. You still need to conduct your own analysis.